The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Segment loss | -56,790 |
| Depreciation and amortization | 7,725 |
| Stock-based compensation expense | 28,034 |
| Change in contingent consideration | 0 |
| Impairment on ipr&d (note 6) | 0 |
| Interest income | 13,354 |
| Other (expense) income, net (note 12) | -559 |
| Income tax (expense) recovery, net | 1,376 |
| Net loss | -81,130 |
| Depreciation of property and equipment (note 7) | 3,669 |
| Amortization of intangible assets (note 8) | 4,056 |
| Stock-based compensation (note 10e) | 28,034 |
| Amortization and impairment of operating lease right-of-use assets | 3,385 |
| Impairment of acquired ipr&d (note 6) | 0 |
| Deferred income tax expense (recovery) (note 13) | -945 |
| Change in fair value of contingent consideration liability (note 15) | 0 |
| Change in fair value of investments in equity instruments | 0 |
| Unrealized foreign exchange loss (gain) | -532 |
| Accounts receivable | -51,200 |
| Prepaid expenses and other current assets | -6,509 |
| Accounts payable and accrued liabilities | -23,648 |
| Operating lease liabilities | -3,342 |
| Deferred revenue and other consideration | -23,170 |
| Income taxes payable | -45 |
| Net cash used in operating activities | -33,005 |
| Proceeds from issuance of common stock under at-the-market program and from public offerings, net of issuance costs (notes 10a) | 0 |
| Private placement (note 10a) | 4,988 |
| Issuance of common stock on exercise of stock options (note 10e) | 16,904 |
| Issuance of common stock through employee stock purchase plan (note 10f) | 1,425 |
| Purchases of common stock for retirement (note 10c) | 41,695 |
| Deferred financing fees | 181 |
| Net cash (used in) / provided by financing activities | -18,559 |
| Purchases of marketable securities | 196,061 |
| Proceeds from marketable securities | 225,076 |
| Acquisition of property and equipment | 1,521 |
| Acquisition of intangible assets | 831 |
| Net cash provided by / (used in) investing activities | 26,663 |
| Effect of exchange rate changes on cash and cash equivalents | -45 |
| Net change in cash and cash equivalents | -24,946 |
| Cash and cash equivalents, beginning of year | 66,103 |
| Cash and cash equivalents, end of year | 41,157 |
Zymeworks Inc. (ZYME)
Zymeworks Inc. (ZYME)